Skip to main content

Investor Relations

We aim at sustaining a continuous, clear and trustful communication with all our partners and stakeholders.

Integrated diagnostic solutions for critical care settings

We are committed to improving patient outcomes with innovative diagnostic solutions for acute care that allow the diagnosis, outcome prediction, and monitoring of patients with acute medical conditions.

SphingoTec develops and markets innovative in vitro diagnostics solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements to routine clinical practice. We develop biomarkers addressing diagnostically underserved critical care conditions such sepsis, acute heart failure, acute kidney injury, and cardiogenic shock.

SphingoTec is a privately held company with the headquarter in Hennigsdorf near Berlin and with a wholly owned subsidiary in San Diego, USA. We have a long history of biomarker discovery, development and validation at our German location. Our U.S. location is home to the production of our fully developed Point of Care testing platform Nexus IB10.

 

Our investors share our vision of improving patient outcomes

SphingoTec in a nutshell

Our portfolio of tests supports a better management of critically ill patients, where fast and reliable information is essential in taking treatment decisions. We are a fully integrated diagnostics company: our innovative biomarkers are commercially available on the point of care platform Nexus IB10.

The assay portfolio for near patient testing goes beyond innovation: on the Nexus IB10 platform, clinicians can deploy a wide range of commonly used parameters in acute and critical care settings, making the analyzer a useful addition to intensive care units (ICU), emergency departments (ED), and other near patient settings.

Investment Thesis

IB10_2

A unique platform

A rapid point-of-care platform that is a bed-side solution to diagnostic healthcare challenges.

Early stage opportunity

An opportunity of investment in more than 200 patents that could benefit over 60 million patients worldwide.

Skillful team

A skilled international team with a broad scope of experience committed to improve patient lives

An innovative portfolio

Innovative biomarkers for diagnosis, prediction and monitoring of ICU mortality drivers.


Latest News

29. November 2021
SphingoTec announced the appointment of Jörg Menten as its Chief Commercial Officer. In this role, Menten will develop the global commercial strategy, oversee the expansion in diagnostic markets worldwide, strengthen existing customer relations and forge new partnerships with global IVD leaders and pharmaceutical companies.
Read more
09. September 2021
SphingoTec announces a series of presentations demonstrating the utility of its innovative biomarkers in sepsis, positively impacting diagnostic and treatment decisions for critically ill patients.
Read more
31. August 2021
Uniklinik RWTH Aachen and SphingoTec GmbH announce today that novel data on the acute care biomarkers bio-ADM and penKid will be presented at the 40th ISICEM.
Read more

Events & Expos

22. - 25. March 2022

10:59 - 11:00

Brussels, Belgium

The International Symposium on Intensive Care and Emergency Medicine is organized by the Departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Université Libre de…

Read more
23. - 25. February 2022

09:00 - 09:00

Bremen, DE

The Symposium Intensivmedizin + Intensivpflege in Bremen is the largest annual meeting of intensive care physicians and nurses, administrative experts and industry representatives independent of…

Read more
19. - 21. January 2022

09:00 - 13:18

Berlin, DE

The Forum Interdisciplinary Intensive Care Medicine is an advanced training event for medical leaders.

Read more

Contact Investor Relations

Do you have any questions or require more information? Please contact the Investor Relations Team, send us an e-mail or call us.

phone: + 49 (0)330 220 56 5 - 0
email: ir@sphingotec.com

Dr. Angelo Moesslang

Chief Financial Officer and Managing Director

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now